VERTEX PHARMACEUTICALS INC / MA Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$44.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$40.30M, a 232.13% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $30.50M.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$15.60M, a 230.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $12.00M.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $90.90M.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$42.60M, a 258.36% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $26.90M.
- VERTEX PHARMACEUTICALS INC / MA effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$29.20M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$44.00M 10-Q · filed 2026-08-04 | |||||||
| 2026-03-31 | -$40.30M 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | $90.90M 10-K · filed 2026-02-13 | |||||||
| 2025-09-30 | $83.60M 10-Q · filed 2025-11-04 | |||||||
| 2025-06-30 | $87.70M 10-Q · filed 2026-08-04 | |||||||
| 2025-03-31 | $30.50M 10-Q · filed 2026-05-05 | |||||||
| 2024-12-31 | -$42.60M 10-K · filed 2026-02-13 | |||||||
| 2024-09-30 | $4.70M 10-Q · filed 2025-11-04 | |||||||
| 2024-06-30 | -$18.10M 10-Q · filed 2025-08-05 | |||||||
| 2024-03-31 | -$15.60M 10-Q · filed 2025-05-06 | |||||||
| 2023-12-31 | $26.90M 10-K · filed 2026-02-13 | |||||||
| 2023-09-30 | -$500.00K 10-Q · filed 2024-11-05 | |||||||
| 2023-06-30 | $22.00M 10-Q · filed 2024-08-02 | |||||||
| 2023-03-31 | $12.00M 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | -$29.20M 10-K · filed 2025-02-13 | |||||||
| 2022-09-30 | -$70.00M 10-Q · filed 2023-11-07 | |||||||
| 2022-06-30 | -$31.80M 10-Q · filed 2023-08-02 | |||||||
| 2022-03-31 | -$5.90M 10-Q · filed 2023-05-02 | |||||||
| 2021-12-31 | -$13.40M 10-K · filed 2024-02-15 | |||||||
| 2021-09-30 | -$8.50M 10-Q · filed 2022-10-28 | -$8.47M 10-Q · filed 2021-11-03 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-05 | -$11.00K 10-Q · filed 2021-07-30 | ||||||
| 2021-03-31 | -$4.00M 10-Q · filed 2022-05-06 | -$4.03M 10-Q · filed 2021-04-30 | ||||||
| 2020-12-31 | $20.60M 10-K · filed 2023-02-10 | $20.55M 10-K · filed 2021-02-11 | ||||||
| 2020-09-30 | $2.78M 10-Q · filed 2021-11-03 | |||||||
| 2020-06-30 | -$3.38M 10-Q · filed 2021-07-30 | |||||||
| 2020-03-31 | -$6.65M 10-Q · filed 2021-04-30 | |||||||
| 2019-12-31 | $1.60M 10-K · filed 2022-02-09 | $1.64M 10-K · filed 2020-02-13 | ||||||
| 2019-09-30 | -$4.01M 10-Q · filed 2020-10-30 | |||||||
| 2019-06-30 | -$808.00K 10-Q · filed 2020-07-31 | |||||||
| 2019-03-31 | -$378.00K 10-Q · filed 2020-05-01 | |||||||
| 2018-12-31 | -$6.18M 10-K · filed 2021-02-11 | |||||||
| 2018-09-30 | -$4.76M 10-Q · filed 2019-10-31 | |||||||
| 2018-06-30 | -$4.20M 10-Q · filed 2019-08-01 | |||||||
| 2018-03-31 | $1.66M 10-Q · filed 2019-05-01 | |||||||
| 2017-12-31 | $5.80M 10-K · filed 2020-02-13 | |||||||
| 2017-09-30 | $5.00M 10-Q · filed 2018-10-25 | |||||||
| 2017-06-30 | $3.50M 10-Q · filed 2018-07-26 | |||||||
| 2017-03-31 | $1.39M 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |